We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
U.S. FDA approves Bayer’s Xarelto (rovaroxaban) for patients with coronary or peripheral artery disease
The U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), 2.5 mg twice daily, plus aspirin low dose once…
The U.S. Food and Drug Administration has approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant)…
FDA approves Arikayce (amikacin liposome inhalation suspension), a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation.
The U.S. Food and Drug Administration has approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of…
Luxturna (voretigene neparvovec), first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene recommended for authorisation by EMA
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna…
New medicine to treat infections in adults: Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a…
Nerlynx, neratinib, a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who…
The U.S. Food and Drug Administration has approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult…
Cablivi (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired…
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40